Articles: 30.08 August 2019

Optimising investment in polypharmacy

In this editorial, Rupert Payne, Consultant Editor for Prescriber, discusses what progress has been made since the publication King’s Fund report on polypharmacy. 

More details...

The polypharmacy programme in Scotland: realistic prescribing

Since 2012, NHS Scotland has published a series of polypharmacy guidelines to help clinicians address the many medication-related problems arising from multimorbidity. Here, Alpana Mair, Chair of the guideline group, Martin Wilson and Tobias Dreischulte explain how the third and latest edition of the polypharmacy …

More details...

COPD update and new guidance on antibiotics for exacerbations

NICE recently updated its guideline on the diagnosis and management of chronic obstructive pulmonary disease (COPD) and at the same time published new antimicrobial prescribing guidance on managing acute exacerbations of COPD. This article provides a summary of these two documents

More details...

Why isn’t the NHS making the most of biosimilar insulin?

With cheaper biosimilar insulins now reaching the UK market, there are opportunities for potential cost savings in diabetes management. However, uptake in the NHS has so far been low. In this article, Mark Greener explores the possible reasons for this

More details...

Diabetic ketoacidosis – a diagnosis not to be missed

Diabetic ketoacidosis (DKA) is the leading cause of death before the age of 30 in people with type 1 diabetes, therefore prompt diagnosis and treatment is vital. This article provides some clinical case studies to illustrate how the presentation of DKA can vary and offers …

More details...

Diagnosis and management of familial hypercholesterolaemia

Familial hypercholesterolaemia (FH) is the most common monogenic lipid metabolism disorder, affecting up to 1 in 250 people in the UK. Patients with FH have high levels of low-density lipoprotein cholesterol and are at very high risk of premature cardiovascular disease. This article focuses on …

More details...

Semaglutide: a new GLP-1 analogue for type 2 diabetes

Semaglutide (Ozempic) is a new once-weekly glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes. This article examines its efficacy, adverse effects and place in therapy

More details...

Web design and marketing agency Leamington Spa